ID   PANC-1RG7
AC   CVCL_WS13
DR   cancercelllines; CVCL_WS13
DR   Wikidata; Q98128481
RX   PubMed=25394408;
CC   Population: Caucasian.
CC   Doubling time: 33.83 +- 2.15 hours (PubMed=25394408).
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pancreas; UBERON=UBERON_0001264.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0480 ! PANC-1
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 05-10-23; Version: 9
//
RX   PubMed=25394408; DOI=10.3892/or.2014.3599;
RA   Wang C.-F., Zhang W.-W., Fu M.-J., Yang A.-Q., Huang H.-H., Xie J.-M.;
RT   "Establishment of human pancreatic cancer gemcitabine-resistant cell
RT   line with ribonucleotide reductase overexpression.";
RL   Oncol. Rep. 33:383-390(2015).
//